J&J plans for Stelara's sunset years with a diversified future

6 December 2023
johnson_big

American healthcare giant Johnson & Johnson (NYSE: JNJ) has undertaken an in-depth business review, publishing  plans which include the launch of 20 new products by the end of the decade.

The company is working on new therapies in oncology, as well as for immune-mediated and neurological conditions, supporting growth of around 6% towards the end of the forecast period.

A newly-streamlined J&J, which like many big pharma firms has  hived off its consumer health division, is looking ahead to replace lost revenues once blockbuster Stelara (ustekinumab) comes off patent.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical